InsiderSignalSign in

← Insider buys

SPRY

ARS Pharmaceuticals, Inc. · Healthcare

Insiders sold $284K of ARS Pharmaceuticals, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$284KSold, 12 mo

$400.8MMarket cap

SPRY over the last year

No insider buys filed in this year

SPRY after insider buys

3 months after each buy, from the first price a copier could get.

+41.4%Average

+34.1 ptsVs S&P 500

3 of 3Higher

3 buys since 2022 with 3 months of prices.

Every filing

62 insider filings since 2022, newest first

Eric Karas · Chief Commercial Officer

$250K−67.2%Jun 13

Alexander A Fitzpatrick · Chief Legal Officer

$34K−3.6%Jun 13

Justin Chakma · Chief Business Officer

$1.4M−42.0%Nov 27

Richard E Lowenthal · President, CEO and 10% owner

$1.4M−1.0%Nov 21

Sarina Tanimoto · Chief Medical Officer and 10% owner

$1.4M−1.0%Nov 21

Sarina Tanimoto · Chief Medical Officer and 10% owner

$1.7M−1.0%Nov 14

Richard E Lowenthal · President, CEO and 10% owner

$1.7M−1.0%Nov 14

James E Flynn · 10% owner

$10.1M−5.0%Nov 13

Kathleen D. Scott · CFO

$200K−49.0%Oct 17

Sarina Tanimoto · Chief Medical Officer and 10% owner

$1.5M−1.0%Oct 17

Richard E Lowenthal · President, CEO and 10% owner

$1.5M−1.0%Oct 17

Sarina Tanimoto · Chief Medical Officer and 10% owner

$1.4M−1.0%Oct 10

Richard E Lowenthal · President, CEO and 10% owner

$1.4M−1.0%Oct 10

Eric Karas · Chief Commercial Officer

$140K−64.0%Sep 19

Sarina Tanimoto · Chief Medical Officer and 10% owner

$1.3M−1.0%Sep 19

Richard E Lowenthal · President, CEO and 10% owner

$1.3M−1.0%Sep 19

Sarina Tanimoto · Chief Medical Officer and 10% owner

$1.1M−1.0%Sep 12

Richard E Lowenthal · President, CEO and 10% owner

$1.1M−1.0%Sep 12

Peter A. Thompson · Director

$1.1M−1.0%Aug 28

Orbimed Advisors LLC · Director

$1.1M−1.0%Aug 28

Peter A. Thompson · Director

$11.5M−9.0%Aug 23

Orbimed Advisors LLC · Director

$11.5M−9.0%Aug 23

Brian Dorsey · COO

$750K−89.0%Aug 21

Eric Karas · Chief Commercial Officer

$140K−64.0%Aug 21

Kathleen D. Scott · CFO

$200K−49.0%Aug 21

Sarina Tanimoto · Chief Medical Officer and 10% owner

$1.5M−1.0%Aug 21

Richard E Lowenthal · President, CEO and 10% owner

$1.5M−1.0%Aug 21

Brian Dorsey · COO

$390K−83.0%Aug 15

Sarina Tanimoto · Chief Medical Officer and 10% owner

$1.2M−1.0%Aug 15

Richard E Lowenthal · President, CEO and 10% owner

$1.2M−1.0%Aug 15

Richard E Lowenthal · President, CEO and 10% owner

$1.1M−1.0%Jul 18

Sarina Tanimoto · Chief Medical Officer and 10% owner

$1.1M−1.0%Jul 18

Sarina Tanimoto · Chief Medical Officer and 10% owner

$962K−1.0%Jul 11

Richard E Lowenthal · President, CEO and 10% owner

$962K−1.0%Jul 11

Richard E Lowenthal · President, CEO and 10% owner

$914K−1.0%Jun 13

Sarina Tanimoto · Chief Medical Officer and 10% owner

$914K−1.0%Jun 13

Sarina Tanimoto · Chief Medical Officer and 10% owner

$905K−1.0%May 16

Richard E Lowenthal · President, CEO and 10% owner

$905K−1.0%May 16

Sarina Tanimoto · Chief Medical Officer and 10% owner

$934K−1.0%May 9

Richard E Lowenthal · President, CEO and 10% owner

$934K−1.0%May 9

Sarina Tanimoto · Chief Medical Officer and 10% owner

$928K−1.0%Apr 17

Richard E Lowenthal · President, CEO and 10% owner

$928K−1.0%Apr 17

Sarina Tanimoto · Chief Medical Officer and 10% owner

$928K−1.0%Apr 10

Richard E Lowenthal · President, CEO and 10% owner

$928K−1.0%Apr 10

Richard E Lowenthal · President, CEO and 10% owner

$890K−1.0%Mar 26

Sarina Tanimoto · Chief Medical Officer and 10% owner

$890K−1.0%Mar 26

Richard E Lowenthal · President, CEO and 10% owner

$914K−1.0%Mar 15

Sarina Tanimoto · Chief Medical Officer and 10% owner

$914K−1.0%Mar 15

Sarina Tanimoto · Chief Medical Officer and 10% owner

Richard E Lowenthal · President, CEO and 10% owner

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.